Status:
COMPLETED
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
Lead Sponsor:
M Abdur Rahim Medical College and Hospital
Collaborating Sponsors:
First Affiliated Hospital Xi'an Jiaotong University
Cox's Bazar 250 Bed District Sadar Hospital
Conditions:
Covid19
Covid-19 ARDS
Eligibility:
All Genders
16-80 years
Phase:
PHASE3
Brief Summary
This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavir...
Eligibility Criteria
Inclusion
- Severe COVID-19 patients require hospitalization under HDU/ICU. The SARS-CoV-2 infection will be confirmed by RT PCR / CT Chest in every case.
Exclusion
- Participants with uncontrolled clinical status who were hospitalized from the before.
- Contraindication / possible drug interaction.
- Participants who have any severe and/or uncontrolled medical conditions like, Severe ischemic heart disease, epilepsy, malignancy, Pulmonary/renal/hepatic disease, AIDS, Pulmonary TB, pregnancy, Corpulmonale, and etc.
Key Trial Info
Start Date :
August 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 10 2021
Estimated Enrollment :
205 Patients enrolled
Trial Details
Trial ID
NCT04678739
Start Date
August 15 2020
End Date
February 10 2021
Last Update
April 2 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chattogram General Hospital
Chittagong, Bangladesh, 4000
2
Cox's Bazar 250 Bed District Sadar Hospital
Cox’s Bāzār, Bangladesh
3
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh, 5200
4
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh